CorMedix Inc. to Present at Salomon Bio Investment and Leadership Conference

BEDMINSTER, NJ / ACCESSWIRE / November 13, 2015 / CorMedix Inc. (NYSE MKT: CRMD) announced today that Randy Milby, CEO, will provide a company overview at the Salomon Bio Investment and Leadership Conference on November 16, 2015. The presentation will take place at 11 am ET in the Convene Conference Center, 101 Park Avenue, New York, NY 10178. Please visit the CorMedix website at www.CorMedix.com.

About CorMedix

CorMedix Inc. is a commercial-stage biopharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases. CorMedix’s first commercial product in Europe is Neutrolin(R), a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients, in addition to oncology patients, critical care patients, and patients receiving total parenteral nutrition, IV hydration, and/or IV medications. Plans are in progress to expand commercial distribution into the United States, Asia, and the Middle East upon appropriate regulatory approval. For more information visit: www.cormedix.com.

Investors:

CorMedix Inc.
Randy Milby
(908) 517-9489

SOURCE: CorMedix Inc.

ReleaseID: 433586